Please assess the completion status of the following clinical trial:

Trial Title: Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed hormone-refractory metastatic prostate cancer~  * Patients who have been recently withdrawn from treatment with bicalutamide or flutamide must demonstrate progression of disease~* Measurable disease OR prostate-specific antigen level ≥ 10 ng/mL~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Estimated life expectancy ≥ 6 months~* Absolute neutrophil count ≥ 1,500/mm³~* Hemoglobin ≥ 8 g/dL~* Platelet count ≥ 100,000/mm³~* Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min~* Bilirubin normal~* AST, ALT, and alkaline phosphatase (AP) must meet 1 of the following criteria:~  * AP normal and AST and ALT ≤ 2.5 times upper limit of normal (ULN)~ * AP elevated and AST and ALT normal~* No history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80~* No peripheral neuropathy \> grade 1~* No concurrent active infections~* No concurrent major depression or suicidal ideation~* No concurrent medical condition that would preclude study participation~* No known HIV positivity~* Fertile patients must use effective contraception during and for 10 weeks after completion of study therapy~PRIOR CONCURRENT THERAPY:~* Recovered from prior surgery or radiotherapy~* No prior chemotherapy, retinoids, or interferon therapy~* More than 4 weeks since prior flutamide~* More than 6 weeks since prior bicalutamide

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).